{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-004532","form_type":"8-K","ticker":"MTVA","cik":"0001638287","company_name":"MetaVia Inc.","filed_at":"2026-01-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.715366+00:00","generated_at":"2026-05-16T09:51:56.511365+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MetaVia closes $9.3M public offering with full over-allotment; net proceeds ~$7.7M for DA-1726","bullets":["Closed offering of 3,005,574 shares/equivalents + 4,508,361 Series C and Series D Warrants at $3.10 each.","Net proceeds to MetaVia approximately $7.7 million after underwriting discounts and expenses.","Series C Warrants ($3.10 exercise, 5-year term); Series D Warrants ($3.10 exercise, 2-year term, callable).","Series D Warrants callable after positive Phase 1b Part III data for DA-1726 and stock price >$4.65 for 20 days.","Proceeds to fund working capital and clinical development of DA-1726 for obesity treatment."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-004532","json":"https://secwatch.observer/filing/0001104659-26-004532.json","markdown":"https://secwatch.observer/filing/0001104659-26-004532.md","text":"https://secwatch.observer/filing/0001104659-26-004532.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638287/000110465926004532/0001104659-26-004532-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638287/000110465926004532/tm263364d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T09:51:56.511365+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"32430f786cf1cd75db394037d4f2aba19c226e61","claim":"MetaVia Inc. entered into Underwriting Agreement with Ladenburg Thalmann & Co. Inc. valued at Issued and sold 614,840 Class A Units at $3.10 per unit and 1,998,704 Class B Units at $3.099 per un (effective 2026-01-15).","evidence_excerpt":"On January 15, 2026, MetaVia Inc. (the “ Company ”) entered into an Underwriting Agreement (the “ Underwriting Agreement ”) with Ladenburg Thalmann & Co. Inc. (the “ Underwriter ”), pursuant to which the Company issued and sold, in an underwritten public offering by the Company (the “ Public Offering ”), (i) 614,840 Class A Units (the “ Class A Units ”), with each Class A Unit consisting of (A) one share of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), (B) 1.5 Series C Common Warrants to purchase 1.5 shares of Common Stock (the “ Series C Common Warrants ”), and (C) 1.5 Series D Common Warrants to purchase 1.5 shares of Common Stock, at a price of $3.10 per Class A Unit, and (ii) 1,998,704 Class B Units (the “ Class B Units ”), with each Class B Unit consisting of (A) one pre-funded warrant (the “ Pre-Funded Warrants ” and, together with the Series C Common Warrants and the Series D Common Warrants, the “ Warrants ”) to purchase one share of Common Stoc","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1638287/000110465926004532/0001104659-26-004532-index.htm","confidence":0.98,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Ladenburg Thalmann & Co. Inc."},{"label":"Value","value":"Issued and sold 614,840 Class A Units at $3.10 per unit and 1,998,704 Class B Units at $3.099 per un"},{"label":"Effective","value":"2026-01-15"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}